← Leaderboards
Dianna S Howard
University Of Kentucky
$586,292
Attributed
$586,292
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $258.4K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$586,292 · 4
By mechanism
R21$498,277 · 1
M01$88,015 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Kentucky
Same institution · by research overlap
- Jeffrey Niel Keller$8,674,993
- Kyung Bo Kim$6,087,977
- Craig T. Jordan$14,848,921
- Royce Mohan$8,216,905
- Yekaterina Zaytseva$3,658,566
Others in their field
Top investigators on “Acute Myelogenous Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- Brad H. Pollock · University Of Florida$28,646,726
- Gregory H Reaman · National Childhood Cancer Foundation$17,689,961
- Richard Aplenc · University Of Pennsylvania$16,894,374
- Daniel G Tenen · Beth Israel Deaconess Medical Center$16,073,131
Research focus
Acute Myelogenous LeukemiaDrug Screening /EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyP53 Gene /ProteinClinical Trial Phase IiNeoplasm /Cancer Relapse /RecurrenceBortezomibBaseAnthracyclinesElderlyClinical TrialsClinical Trials, Phase IClinical Trials, Phase IiDose-LimitingClinical ResearchApoptosisDisease RemissionDosageDoseCytogeneticsCellsComputer Retrieval Of Information On Scientific Projects DatabaseCombination Chemotherapy
Grant awards (5)
BORTEZOMIB WITH WEEKLY IDARUBICIN FOR THE TREATMENT OF AML$19,168
M01 · FY2007 · RR · contact PI
BORTEZOMIB WITH WEEKLY IDARUBICIN FOR THE TREATMENT OF AML$51,114
M01 · FY2006 · RR · contact PI
Bortezomib and Idarubicin in the Treatment of AML$240,714
R21 · FY2005 · CA
BORTEZOMIB WITH WEEKLY IDARUBICIN FOR THE TREATMENT OF AML$17,733
M01 · FY2005 · RR
Bortezomib and Idarubicin in the Treatment of AML$257,563
R21 · FY2004 · CA